{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.16","value":"0.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"}],"units":"Participants"}],"description":"The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The instrument is applicable to a wide range of health conditions and treatments and results in a single index score and a visual analog scale (VAS) score. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension comprises three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state is defined by combining one level from each of the five dimensions. EQ-5D index values range from -0.59 to 1.00. Higher EQ-5D Index scores represent better health status.","dispersionType":"Standard Deviation","groups":[{"description":"Romiplostim administered to adult participants subcutaneously weekly at doses up to 30 µg/kg based on platelet counts. After Amendment 1 the maximum weekly dose was reduced to 15 µg/kg, and after Amendment 2 the maximum weekly dose was reduced to 10 µg/kg. However, participants enrolled prior to Amendment 2 who were receiving \\>10 µg/kg were permitted to remain on that higher dose, but could not increase their dose. In addition, if the participant's dose was decreased, it could not be increased to \\>10 µg/kg.","id":"OG000","title":"Romiplostim in Adults"}],"paramType":"MEAN","populationDescription":"Full analysis set with available data. Patient reported outcomes were only analyzed in adult participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 48","title":"Change From Baseline in Euroqol-5D (EQ-5D) Index Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}